This trial is active, not recruiting.

Condition lung adenocarcinoma
Treatment sequencing
Sponsor Hospices Civils de Lyon
Start date January 2014
End date January 2016
Trial size 152 participants
Trial identifier NCT02843711, 69HCL15_0161


LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data.

Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective
Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.

Primary Outcomes

Genomic DNA Mutation
time frame: at diagnosis (Day 0)

Eligibility Criteria

Male or female participants from 18 years up to 99 years old.

Inclusion Criteria: - Adults - lung adenocarcinoma - Surgical specimen Exclusion Criteria: - not adenocarcinoma subtype of lung cancer - Tumour biopsy - insufficient material for DNA extraction

Additional Information

Official title Molecular Analysis of 150 Lung Adenocarcinoma With Corresponding Histopathological and Clinical Data Available
Principal investigator Marie BREVET, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Hospices Civils de Lyon.